Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
targeted therapies
Biotech
Tyra banks $173M to bring cancer resistance programs into clinic
Tyra is the latest biotech to rake in an upsized IPO. Its $172.8 million deal will advance three programs targeting drug-resistant cancers.
Amirah Al Idrus
Sep 15, 2021 10:20am
AstraZeneca, Thermo Fisher launch multiyear diagnostic project
Sep 1, 2021 10:45am
Nuvalent banks $166M IPO to push resistance-beating cancer drugs
Jul 29, 2021 11:20am
Erasca nabs $300M IPO to attack cancer's favorite pathway
Jul 16, 2021 10:10am
Ionis pays $45M to expand oligonucleotide delivery toolkit
Jul 13, 2021 8:20am
Blueprint adds another BMS vet to its roster with new CSO
May 17, 2021 10:25am
